Who
Michael D. Blaszyk
Director
Company insider
Files Form 4 as: Director, ImmunityBio; Director, NantHealth; Director, APP Pharmaceuticals.
In numbers
- Trades disclosed
- 26
- Buys
- 1
- Sells
- 0
- Bought
- $198K
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 1 Aug 2006
- Last trade
- 9 Jun 2026
- Last filed
- 10 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Jun 2026filed 10 Jun 2026 | IBRX ImmunityBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —65,600 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | IBRX ImmunityBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —65,600 at $0.00 | filing |
| 18 Jun 2025filed 20 Jun 2025 | IBRX ImmunityBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —162,786 at $0.00 | filing |
| 11 Jun 2024filed 13 Jun 2024 | IBRX ImmunityBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —77,633 at $0.00 | filing |
| 13 Jun 2023filed 15 Jun 2023 | IBRX ImmunityBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —158,263 at $0.00 | filing |
| 5 Jun 2023filed 5 Jun 2023 | IBRX ImmunityBioBiotechnology | SEC FORM 4 Bought | $64K23,430 at $2.72 | filing |
| 5 Jun 2023filed 5 Jun 2023 | IBRX ImmunityBioBiotechnology | SEC FORM 4 Bought | $133K48,000 at $2.77 | filing |
| 5 Jun 2023filed 5 Jun 2023 | IBRX ImmunityBioBiotechnology | SEC FORM 4 Bought | $1,334485 at $2.75 | filing |
| 14 Jun 2022filed 15 Jun 2022 | IBRX ImmunityBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —167,937 at $0.00 | filing |
| 9 Jun 2022filed 10 Jun 2022 | NantHealthoption or derivative | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 16 Jun 2021filed 26 Jul 2021 | NantHealthoption or derivative | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 10 Jun 2021filed 14 Jun 2021 | IBRX ImmunityBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —26,064 at $0.00 | filing |
| 10 Jun 2020filed 11 Jun 2020 | IBRX ImmunityBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 21 May 2020filed 26 May 2020 | NantHealthoption or derivative | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 13 Jun 2019filed 17 Jun 2019 | NantHealthoption or derivative | SEC FORM 4 Code A | —301,908 at $0.00 | filing |
| 6 Jun 2019filed 7 Jun 2019 | IBRX ImmunityBioBiotechnology | SEC FORM 4 Code A | —92,592 at $0.00 | filing |
| 6 Sep 2018filed 7 Sep 2018 | NantHealth | SEC FORM 4 Code A | —45,002 at $0.00 | filing |
| 6 Sep 2018filed 7 Sep 2018 | NantHealth | SEC FORM 4 Code A | —52,910 at $0.00 | filing |
| 7 Jun 2018filed 11 Jun 2018 | IBRX ImmunityBioBiotechnology | SEC FORM 4 Code A | —27,322 at $0.00 | filing |
| 6 Nov 2017filed 8 Nov 2017 | NantHealth | SEC FORM 4 Code A | —50,868 at $0.00 | filing |
News
ImmunityBio (NASDAQ:IBRX) Shares Down 6.4% – Here's WhyIBRX · dailypolitical.com · 19 Oct 2026
0 headlines in the last 90 days name Michael D. Blaszyk; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.